摘要
目的 研究复方斑蝥胶囊联合化疗非小细胞肺癌(NSCLC)的效果及对细胞角蛋白19片段(Cyfra21-1)、β2-微球蛋白(β2-MG)、红细胞分布宽度(RDW)和预后的影响。方法 选取2018年12月至2021年12月于淮南市新华医院肿瘤科进行治疗的NSCLC患者88例,按照治疗方法的不同分为观察组(n=44)和对照组(n=44)。对照组患者均给予吉西他滨与顺铂(GP)进行化疗,观察组在此基础上给予口服复方斑蝥胶囊治疗。比较两组患者的治疗效果、Cyfra21-1、β2-MG、RDW以及预后情况。采用卡普兰-米耶尔生存曲线分析了不同治疗方法对3年内生存率的影响。结果 观察组治疗的有效率以及疾病控制率均高于对照组(χ^(2)=4.555、6.465,P<0.05)。治疗后观察组Cyfra21-1、β2-MG、RDW低于对照组,差异有统计学意义(t=5.182、8.153、3.136,P<0.05)。观察组的胃肠道反应以及骨髓抑制发生率明显低于对照组(χ^(2)=4.555、5.066,P<0.05)。观察组在各时间段的存活率均优于对照组患者(χ^(2)=6.026、4.555、4.141、4.470,P<0.05)。结论 复方斑蝥胶囊联合化疗NSCLC的临床疗效显著,能够有效地降低Cyfra21-1、β2-MG、RDW,提高患者的远期临床疗效,安全性高,具有较好的临床价值。
Objective To study the effect of Compound Banthari Capsule combined with chemotherapy for non-small cell lung cancer(NSCLC)and its effects on cytokeratin 19 fragment(Cyfra21-1),β2-microglobulin(β2-MG),red blood cell distribution width(RDW)and prognostic impact. Methods A total of88 patients with NSCLC who were treated in the Oncology Department of Huainan Xinhua Hospital from December 2018 to December 2021 were selected and divided into the observation group(n=44)and the control group(n=44)according to different treatment methods. Both groups were given gemcitabine and cisplatin(GP)for chemotherapy,the control group was given oral placebo on this basis,and the observation group was given oral Compound Banthari Capsules on this basis. The treatment effect,Cyfra21-1,β2-MG,RDW and prognosis of the two groups of patients were compared. The Kaplan-Miyer survival curve was used to analyze the effect of different treatment methods on the 3-year survival rate. Results The effective rate and disease control rate in the observation group were higher than those in the control group(χ^(2)=4.555,6.465,P<0.05). After treatment,Cyfra21-1β2-MG and RDW were lower than those in the control group(t=5.182,8.153,3.136,P<0.05). The incidences of gastrointestinal reaction and bone marrow suppression in the observation group were significantly lower than those in the control group(χ^(2)=4.555,5.066,P<0.05). The survival rate of the observation group was better than that of the control group in each time(χ^(2)=6.026,4.555,4.141,4.470,P<0.05). Conclusion The clinical efficacy of Fufang Banthari Capsule combined with chemotherapy for NSCLC is significant,it can effectively reduce Cyfra21-1,β2-MG,RDW,and improve the long-term clinical efficacy of patients. It is safe and has good clinical value.
作者
夏丽丽
陆友国
张波
朱洋
XIA Lili;LU Youguo;ZHANG Bo;ZHU Yang(Department of Medical Oncology,Xinhua Hospital,Huainan,Anhui,China,232052;Department of Nephrology,Xinhua Hospital,Huainan,Anhui,China,232052)
出处
《分子诊断与治疗杂志》
2023年第1期111-114,119,共5页
Journal of Molecular Diagnostics and Therapy
基金
安徽省重点研究和开发项目(1804h08020267)。
作者简介
通信作者:夏丽丽,E⁃mail:xiatian66880928@126.com。
